The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts

Molecular Cancer Research

Volumn 7, Issue 4, 2009, Pages 476-488

  De Vries, Teun J ^a,d   Mullender, Margriet G ^b   Van Duin, Marion A ^a   Semeins, Cornelis M ^a   James, Neil ^c   Green, Tim P ^c   Everts, Vincent ^a   Klein Nulend, Jenneke ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ASTRAZENECA   (United Kingdom)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; 1,3 BENZODIOXOLE DERIVATIVE; ACTIN; MESSENGER RNA; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 (2 (4 METHYLPIPERAZIN 1 YL)ETHOXY) 5 (TETRAHYDRO 2H PYRAN 4 YLOXY)QUINAZOLIN 4 AMINE; N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-(2-(4-METHYLPIPERAZIN-1-YL)ETHOXY)-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE; PROTEIN KINASE P60; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; EXPERIMENTAL RABBIT; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ANIMAL; BONE; CELL ADHESION; CELL CULTURE; CELL MOTION; COCULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FETUS; GENETICS; HUMAN; METABOLISM; MONONUCLEAR CELL; ORGAN CULTURE TECHNIQUE; OSTEOLYSIS; PHOSPHORYLATION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKULL; WESTERN BLOTTING;

ORYCTOLAGUS CUNICULUS;

ACTINS; ANIMALS; BENZODIOXOLES; BLOTTING, WESTERN; BONE AND BONES; BONE RESORPTION; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; FETUS; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; ORGAN CULTURE TECHNIQUES; OSTEOCLASTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUINAZOLINES; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKULL;

EID: 65549145064     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0219     Document Type: Article

References (43)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176 (Pubitemid 32452017)
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342 (Pubitemid 40852708)
3. Perez-Amodio S, Beertsen W, Everts V. (Pre-)osteoclasts induce retraction of osteoblasts prior to their fusion to osteoclasts. J Bone Miner Res 2004;19: 1722-1731 (Pubitemid 41094336)
4. Saltel F, Chabadel A, Zhao Y, et al. Transmigration: a new property of mature multinucleated osteoclasts. J Bone Miner Res 2006;21:1913-1923.
5. Jurdic P, Saltel F, Chabadel A, Destaing O. Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol 2006;85:195-202.
6. 3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000;105: 433-440
7. 3 integrins and associated proteins in Src-deficient or tyrphostin A9-treated osteoclasts. J Cell Sci 2001; 114:149-160
8. Stenbeck G. Formation and function of the ruffled border in osteoclasts. Semin Cell Dev Biol 2002;13:285-292 (Pubitemid 35304514)
9. Horne WC, Neff L, Chatterjee D, Lomri A, Levy JB, Baron R. Osteoclasts express high levels of pp60c-src in association with intracellular membranes. J Cell Biol 1992;119:1003-1013
10. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci U S A 1993;90:4485-4489 (Pubitemid 23148929)
11. Horne WC, Sanjay A, Bruzzaniti A, Baron R. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev 2005;208:106-125 (Pubitemid 41746388)
12. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90:1622-1627
13. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702. (Pubitemid 121001157)
14. Schwartzberg PL, Xing L, Hoffmann O, et al. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev 1997;11:2835-2844
15. Boyce BF, Xing L, Yao Z, et al. SRC inhibitors in metastatic bone disease. Clin Cancer Res 2006;12:6291-5s.
16. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491
17. Missbach M, Jeschke M, Feyen J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999;24: 437-449
18. Recchia I, Rucci N, Funari A, et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 2004;34:65-79. (Pubitemid 38142435)
19. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006;318:161-172 (Pubitemid 43920753)
20. Hennequin LF, Allen J, Breed J, et al. N-(5-Chloro-1,3-benzodioxol-4-yl)- 7- [2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin- 4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006;49:6465-6488
21. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263-274 (Pubitemid 43945756)
22. Finkelman RD, Torti FM, Lipton A, et al. A phase II pilot study of safety and effects on bone resorption of AZD0530 in prostate or breast cancer patients with bone metastases. J Bone Miner Res 2007;22:S409.
23. Hannon RA, Clack G, Gallagher N, Macpherson M, Marshall A, Eastell R. The effect of AZD0530, a highly selective Src inhibitor, on bone turnover in healthy males. Bone 2005;36:S135.
24. Hannon RA, Finkelman RD, Clack G, et al. Effect on bone turnover of the potent, once-daily, oral Src inhibitor AZD0530 in patients with advanced solid malignancies. J Bone Miner Res 2007;22:S410.
25. Everts V, Korper W, Jansen DC, et al. Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 1999;13:1219-1230
26. Tanaka Y, Maruo A, Fujii K, et al. Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: characteristic involvement of cell cycle regulators. J Bone Miner Res 2000;15:1912-1923.
27. Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol 2005;203: 573-582 (Pubitemid 40629020)
28. Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-5033
29. De Vries TJ, Schoenmaker T, Wattanaroonwong N, et al. Gingival fibroblasts are better at inhibiting osteoclast formation than periodontal ligament fibroblasts. J Cell Biochem 2006;98:370-382
30. Hiscox S, Morgan L, Green T, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006;13 Suppl 1:S53-9.
31. Kumagai N, Ohno K, Tameshige R, et al. Induction of mouse c-src in RAW264 cells is dependent on AP-1 and NF-κB and important for progression to multinucleated cell formation. Biochem Biophys Res Commun 2004;325: 758-768
32. Stein PL, Vogel H, Soriano P. Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev 1994;8:1999-2007.
33. Faccio R, Zou W, Colaianni G, Teitelbaum SL, Ross FP. High dose M-CSF partially rescues the Dap12-/- osteoclast phenotype. J Cell Biochem 2003;90: 871-883 (Pubitemid 37467103)
34. 3 integrinand macrophage colony stimulating factor-mediated signals on phospholipase Cγ in prefusion osteoclasts. J Cell Biol 2001;152:361-373
35. Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 2006;12:6258-63s.
36. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468
37. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621
38. Klein-Nulend J, Raisz LG. Effects of two inhibitors of anion transport on bone resorption in organ culture. Endocrinology 1989;125:1019-1024 (Pubitemid 19205101)
39. Bakker AD, Klein-Nulend J, Tanck E, Albers GH, Lips P, Burger EH. Additive effects of estrogen and mechanical stress on nitric oxide and prostaglandin E2 production by bone cells from osteoporotic donors. Osteoporos Int 2005;16:983-989 (Pubitemid 41127109)
40. Faust J, Lacey DL, Hunt P, et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem 1999;72:67-80.
41. Olivier BJ, Schoenmaker T, Mebius RE, et al. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia. Hepatology 2008;47:259-267
42. Tjoa STS, De Vries TJ, Schoenmaker T, Kelder A, Loos BG, Everts V. Formation of osteoclast-like cells from peripheral blood of periodontitis patients occurs without supplementation of M-CSF. J Clin Periodontol 2008; 35:568-575
43. De Vries TJ, Fourkour A, Punt CJA, et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative PCR. Br J Cancer 1999;80: 883-891